NO313180B1 - Bensökende alfapartikkel emitterende radiofarmasöytika - Google Patents

Bensökende alfapartikkel emitterende radiofarmasöytika Download PDF

Info

Publication number
NO313180B1
NO313180B1 NO20003457A NO20003457A NO313180B1 NO 313180 B1 NO313180 B1 NO 313180B1 NO 20003457 A NO20003457 A NO 20003457A NO 20003457 A NO20003457 A NO 20003457A NO 313180 B1 NO313180 B1 NO 313180B1
Authority
NO
Norway
Prior art keywords
bone
stated
treatment
actinium
thorium
Prior art date
Application number
NO20003457A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003457L (no
NO20003457D0 (no
Inventor
Roy H Larsen
Gjermund Henriksen
Original Assignee
Anticancer Therapeutic Inv Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inv Sa filed Critical Anticancer Therapeutic Inv Sa
Priority to NO20003457A priority Critical patent/NO313180B1/no
Publication of NO20003457D0 publication Critical patent/NO20003457D0/no
Priority to US10/332,056 priority patent/US7056275B2/en
Priority to CA002413736A priority patent/CA2413736C/en
Priority to SI200130456T priority patent/SI1296722T1/sl
Priority to AU6773401A priority patent/AU6773401A/xx
Priority to EA200201258A priority patent/EA004899B1/ru
Priority to KR1020037000060A priority patent/KR100892002B1/ko
Priority to PCT/GB2001/002996 priority patent/WO2002005859A2/en
Priority to PL366070A priority patent/PL206209B1/pl
Priority to CZ20030334A priority patent/CZ299087B6/cs
Priority to DE60113683T priority patent/DE60113683T2/de
Priority to AT01945519T priority patent/ATE305313T1/de
Priority to JP2002511790A priority patent/JP5219325B2/ja
Priority to EP01945519A priority patent/EP1296722B1/en
Priority to ES01945519T priority patent/ES2250419T3/es
Priority to DK01945519T priority patent/DK1296722T3/da
Priority to AU2001267734A priority patent/AU2001267734B2/en
Publication of NO20003457L publication Critical patent/NO20003457L/no
Publication of NO313180B1 publication Critical patent/NO313180B1/no
Priority to US11/337,385 priority patent/US7335154B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
NO20003457A 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika NO313180B1 (no)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika
AU2001267734A AU2001267734B2 (en) 2000-07-04 2001-07-04 Radiotherapy
PL366070A PL206209B1 (pl) 2000-07-04 2001-07-04 Zastosowanie emitującego cząstki alfa radionuklidu aktynu albo toru lub jego kompleksu skierowanego docelowo do kości, kompozycja radiofarmaceutyczna, skierowany docelowo do kości kompleks radionuklidu i jego zastosowanie w medycynie oraz zestaw do leczenia powierzchni kości albo nowotworów kośćca
DE60113683T DE60113683T2 (de) 2000-07-04 2001-07-04 Radiotherapy
SI200130456T SI1296722T1 (sl) 2000-07-04 2001-07-04 Radioterapija
AU6773401A AU6773401A (en) 2000-07-04 2001-07-04 Method of radiotherapy
EA200201258A EA004899B1 (ru) 2000-07-04 2001-07-04 Способ лучевой терапии
KR1020037000060A KR100892002B1 (ko) 2000-07-04 2001-07-04 방사선 치료 방법
PCT/GB2001/002996 WO2002005859A2 (en) 2000-07-04 2001-07-04 Radiotherapy
US10/332,056 US7056275B2 (en) 2000-07-04 2001-07-04 Radiotherapy
CZ20030334A CZ299087B6 (cs) 2000-07-04 2001-07-04 Farmaceutický prostredek
CA002413736A CA2413736C (en) 2000-07-04 2001-07-04 Thorium or actinium radionuclides for endoradionuclide therapy
AT01945519T ATE305313T1 (de) 2000-07-04 2001-07-04 Radiotherapy
JP2002511790A JP5219325B2 (ja) 2000-07-04 2001-07-04 骨標的錯体
EP01945519A EP1296722B1 (en) 2000-07-04 2001-07-04 Radiotherapy
ES01945519T ES2250419T3 (es) 2000-07-04 2001-07-04 Radioterapia.
DK01945519T DK1296722T3 (da) 2000-07-04 2001-07-04 Radioterapi
US11/337,385 US7335154B2 (en) 2000-07-04 2006-01-23 Radiotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika

Publications (3)

Publication Number Publication Date
NO20003457D0 NO20003457D0 (no) 2000-07-04
NO20003457L NO20003457L (no) 2002-01-07
NO313180B1 true NO313180B1 (no) 2002-08-26

Family

ID=19911348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika

Country Status (15)

Country Link
US (2) US7056275B2 (cs)
EP (1) EP1296722B1 (cs)
JP (1) JP5219325B2 (cs)
KR (1) KR100892002B1 (cs)
AT (1) ATE305313T1 (cs)
AU (2) AU2001267734B2 (cs)
CA (1) CA2413736C (cs)
CZ (1) CZ299087B6 (cs)
DE (1) DE60113683T2 (cs)
DK (1) DK1296722T3 (cs)
EA (1) EA004899B1 (cs)
ES (1) ES2250419T3 (cs)
NO (1) NO313180B1 (cs)
PL (1) PL206209B1 (cs)
WO (1) WO2002005859A2 (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
HUP0203743A2 (en) * 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
NZ595758A (en) 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
US8142758B2 (en) * 2004-02-20 2012-03-27 Algeta As Alpha-emitting hydroxyapatite particles
CA2570191C (en) * 2004-06-25 2015-04-28 The European Community, Represented By The European Commission Radionuclides for medical use
LU91085B1 (en) * 2004-06-25 2005-12-27 European Community Radionuclides for medical use.
US7794691B2 (en) 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
EP2044090B1 (en) 2006-07-10 2015-04-08 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
FR2913970B1 (fr) * 2007-03-19 2009-06-12 Cogema Production de thorium 228 a partir d'un sel de thorium naturel
US20080249398A1 (en) * 2007-04-09 2008-10-09 Harder George Fred Hybrid Source Containing Multi-Radionuclides for Use in Radiation Therapy
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
US9202602B2 (en) * 2010-02-10 2015-12-01 Uchicago Argonne, Llc Production of isotopes using high power proton beams
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) 2016-01-05 2016-02-17 Bayer As Isotope purification method
US11260136B2 (en) 2016-03-24 2022-03-01 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
US20190298865A1 (en) 2016-06-10 2019-10-03 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
US11529432B2 (en) 2017-05-11 2022-12-20 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
MX2020009940A (es) 2018-04-02 2020-10-16 Alpha Tau Medical Ltd Liberacion controlada de radionucleidos.
FR3088769B1 (fr) 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
US20220152228A1 (en) * 2019-03-01 2022-05-19 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
AU2020398382B2 (en) 2019-12-05 2024-09-19 Sciencons AS Production of highly purified 212Pb
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата
EP4262888A4 (en) 2020-12-16 2024-10-30 Alpha Tau Medical Ltd. DIFFUSION ALPHA-EMITTER RADIATION THERAPY WITH IMPROVED BETA TREATMENT
KR102545315B1 (ko) 2021-01-05 2023-06-20 한국과학기술원 의료용 방사성 동위원소의 생산 방법 및 시스템

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2329147A (en) * 1938-05-07 1943-09-07 Rare Chemicals Inc Stabilized metal sol and method of preparing same
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
WO2000076556A2 (en) * 1999-06-11 2000-12-21 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
HUP0203743A2 (en) 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
ES2250419T3 (es) 2006-04-16
EA200201258A1 (ru) 2003-06-26
KR20030029100A (ko) 2003-04-11
WO2002005859A3 (en) 2002-09-06
DE60113683D1 (en) 2006-02-09
US20030166989A1 (en) 2003-09-04
CA2413736A1 (en) 2002-01-24
EP1296722A2 (en) 2003-04-02
US7335154B2 (en) 2008-02-26
JP2004503331A (ja) 2004-02-05
US20060135842A1 (en) 2006-06-22
EP1296722B1 (en) 2005-09-28
EA004899B1 (ru) 2004-08-26
PL366070A1 (en) 2005-01-24
NO20003457L (no) 2002-01-07
AU2001267734B2 (en) 2005-09-01
US7056275B2 (en) 2006-06-06
CA2413736C (en) 2009-08-18
PL206209B1 (pl) 2010-07-30
WO2002005859A2 (en) 2002-01-24
DK1296722T3 (da) 2006-02-13
AU6773401A (en) 2002-01-30
NO20003457D0 (no) 2000-07-04
KR100892002B1 (ko) 2009-04-07
DE60113683T2 (de) 2006-07-06
ATE305313T1 (de) 2005-10-15
JP5219325B2 (ja) 2013-06-26
CZ299087B6 (cs) 2008-04-23

Similar Documents

Publication Publication Date Title
NO313180B1 (no) Bensökende alfapartikkel emitterende radiofarmasöytika
EP1140212B1 (en) The use of radium-223 to target calcified tissues for pain palliation and therapy of bone cancer
Knapp Jr Rhenium-188-A generator-derived radioisotope for cancer therapy
AU2001267734A1 (en) Radiotherapy
Henriksen et al. 223Ra for endoradiotherapeutic applications prepared from an immobilized 227Ac/227Th source
Henriksen et al. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents
JP2502601B2 (ja) 放射性配位レニウム薬剤の単離および精製方法
Washiyama et al. 227Th-EDTMP: a potential therapeutic agent for bone metastasis
Zhernosekov Radiochemical aspects of production and processing of radiometals for preparation of metalloradiopharmaceuticals
HK1090750B (en) Methods of preparing radium-223, and pharmaceutically acceptable agents and reagent set
NO317110B1 (no) Nytt radiofarmasoytisk preparat

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees